نتائج البحث - "David J. Mauro"

المصدر: Breast cancer research and treatment, vol 163, iss 3
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Baselga, J, Morales, S M, Awada, A, Blum, J L, Tan, A R, Ewertz, M, Cortes, J, Moy, B, Ruddy, K J, Haddad, T, Ciruelos, E M, Vuylsteke, P, Ebbinghaus, S W, Im, E, Eaton, L, Pathiraja, K, Gause, C K, Mauro, D, Jones, M B & Rugo, H S 2017, ' A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer ', Breast Cancer Research and Treatment, vol. 163, no. 3, pp. 535–544 . https://doi.org/10.1007/s10549-017-4199-3Test

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, Phases of clinical research, chemistry.chemical_compound, Breast cancer, 0302 clinical medicine, Exemestane, IGF1R, Receptors, Antineoplastic Combined Chemotherapy Protocols, Monoclonal, Ridaforolimus, Humanized, Cancer, Aromatase Inhibitors, Antibodies, Monoclonal, Middle Aged, Receptors, Estrogen, 6.1 Pharmaceuticals, 030220 oncology & carcinogenesis, mTOR, Female, Patient Safety, Dalotuzumab, Adult, medicine.medical_specialty, medicine.drug_class, Clinical Trials and Supportive Activities, Clinical Sciences, Oncology and Carcinogenesis, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Article, Antibodies, Disease-Free Survival, 03 medical and health sciences, Clinical Research, Internal medicine, medicine, Humans, Oncology & Carcinogenesis, Adverse effect, Protein Kinase Inhibitors, Aged, Sirolimus, Stomatitis, Aromatase inhibitor, business.industry, Evaluation of treatments and therapeutic interventions, medicine.disease, Estrogen, Androstadienes, 030104 developmental biology, chemistry, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f0c820c9a4a3dd16d5dbc64f6079bd5Test
https://doi.org/10.1007/s10549-017-4199-3Test

7

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

المصدر: Journal of Clinical Oncology. 34:3638-3647

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6494747b097fa661fc694cccedb13319Test
https://doi.org/10.1200/jco.2015.66.0084Test

8

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

المصدر: Breast cancer research and treatment, vol 165, iss 3
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, Exemestane, chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, IGF1R, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Ridaforolimus, Humanized, Cancer, Aged, 80 and over, Tumor, Antibodies, Monoclonal, Middle Aged, Metastatic breast cancer, Treatment Outcome, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, Retreatment, mTOR, Female, Dalotuzumab, medicine.drug, Adult, medicine.medical_specialty, medicine.drug_class, Clinical Trials and Supportive Activities, Clinical Sciences, Oncology and Carcinogenesis, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Antibodies, Article, 03 medical and health sciences, Clinical Research, Internal medicine, medicine, Biomarkers, Tumor, Humans, Oncology & Carcinogenesis, Aged, Neoplasm Staging, Sirolimus, Aromatase inhibitor, Everolimus, business.industry, Evaluation of treatments and therapeutic interventions, medicine.disease, Estrogen, Androstadienes, 030104 developmental biology, chemistry, business, Biomarkers

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::012ef3a906b37326705916f88c1e4740Test
https://pubmed.ncbi.nlm.nih.gov/28681171Test

9

Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer

المؤلفون: Christine K. Gause, Marianne Ewertz, Serafin Morales, L Eaton, K Prathiraja, Kathryn J. Ruddy, Scot Ebbinghaus, Joanne L. Blum, Ar Tan, J. Cortes, Beverly Moy, David J. Mauro, Peter Vuylsteke, HS Rugo, Eva Ciruelos, Ellie Im, Tufia C. Haddad, J. Baselga, Ahmad Awada

المصدر: Cancer Research. 73:P2-16

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::979891fdc9ad276e8dbc194351432732Test
https://doi.org/10.1158/0008-5472.sabcs13-p2-16-04Test

10

Abstract OT2-6-13: A randomized phase 2 study of the triplet combination of ridaforolimus (RIDA), dalotuzumab (DALO) and exemestane (EX) compared to the ridaforolimus, exemestane doublet in high proliferation, estrogen receptor positive (ER+) advanced breast cancer

المؤلفون: Joanne L. Blum, Serafin Morales, Noemia Afonso, Ellie Im, Christine K. Gause, L Eaton, Marta Ferreira, Olivier Tredan, David J. Mauro, Kyong Hwa Park, J. Baselga, Jungsil Ro, Ar Tan, A Musolina, J. Cortes, H Rugo

المصدر: Cancer Research. 73:OT2-6

مصطلحات موضوعية: Oncology, Gynecology, Cancer Research, medicine.medical_specialty, Aromatase inhibitor, business.industry, medicine.drug_class, Estrogen receptor, Phases of clinical research, Ridaforolimus, chemistry.chemical_compound, chemistry, Exemestane, Internal medicine, medicine, Clinical endpoint, Progression-free survival, business, PI3K/AKT/mTOR pathway

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::617fed0f3aee0dbd79657aa0d0384fa2Test
https://doi.org/10.1158/0008-5472.sabcs13-ot2-6-13Test

تنقيح النتائج